Coronavirus / COVID

Accuracy of test may be influenced by size of population to be screened and prevalence of COVID-19 within that population.

New details of SARS-CoV-2 have been obtained using 3D modeling, providing crucial insights into the disease.

National Institute of Allergy and Infectious Disease (NIAID) has selected Metabolon to participate in a study on this subject.

Data shows their AZD1222 vaccine met its endpoint and they are preparing regulatory submission for conditional or early approval.

A research team developed an algorithm review estimating not only hospital admissions, but also mortality outcomes in adults with COVID-19.

Study finds that a century-old tuberculosis vaccine could be used in the treatment and prevention of COVID-19.

The third EUA granted to an investigational COVID-19 therapy regimen is indicated for preventing progression from mild, to severe symptoms.

Immunologists have discovered possible treatments for COVID-19 using existing therapies.

This guidance comes less than 24 hours after FDA grants an EUA for its use combined with baricitinib.

The measles-mumps-rubella (MMR) vaccine could potentially aid in the protection against COVID-19.

Two recent studies conducted by Kansas State University researchers resulted in important findings related to the current COVID-19 pandemic.

Meta-analysis shows people infected with SARS-CoV-2 are more highly infectious within the first week of showing symptoms.

This EUA is for the treatment of hospitalized patients who require oxygen.

Patients testing positive for SARS-CoV-2 after recovery and negative tests are re-examined to determine if they are reinfected and/or infectious.

Phase 2 results include a large cohort of seniors in the study.

For the first time, prescribed users at suspected risk of COVID-19 can receive rapid results from home.

The investigational vaccine is being reported as 95% effective.

SARS-CoV-2 outbreaks on 16 different mink farms in the Netherlands have been identified showing transmission between humans and minks.

The data comes from a phase 1/2 trial with the CoronaVac vaccine.

A survey of clinicians found that despite planning for resource limitations during the coronavirus 2019 (COVID-19) pandemic, clinicians still faced difficult decisions at bedside.

New study finds casual links between obese people and the potential for a higher risk of COVID-19 infection

Non-pharmaceutical interventions (NPIs) are not only effective against COVID-19, but also respiratory infections.

Phase 2 data hints the immune response-modulating therapy could play a role in burdened hospital settings.

Further evidence demonstrating the lack of efficacy of hydroxychloroquine as a treatment for coronavirus disease 2019 (COVID-19) was detailed in a new randomized, multicenter, blinded, placebo-controlled study published in JAMA.

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.